![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial |
| Creators Name: | Pecher, G., Haering, A., Kaiser, L. and Thiel, E. |
| Abstract: | Dendritic cells (DC) derived from peripheral blood monocytes are currently being investigated in clinical trials for their role in stimulating the immune system. We performed a phase I/II clinical trial using human autologous DC transfected with cDNA of the human tumor antigen mucin (MUC1) as a vaccine in 10 patients with advanced breast, pancreatic or papillary cancer. After liposomal transfection, flow cytometry testing showed that 2% to 53% of the DC expressed mucin epitopes. Patients were immunized two or three times with 1 million transfected DC injected subcutaneously (s.c.). A vaccine-specific delayed-type hypersensitivity (DTH) reaction was observed in 3 out of 10 patients. After vaccination, 4 patients showed a 2- to 10-fold increase in the frequency of mucin-specific interferon-gamma (IFN-{gamma})-secreting CD8+ T cells. We demonstrated the feasibility and safety of a vaccine consisting of autologous gene-transfected DC, and that immunologic responses could be induced even in patients with pretreated and advanced disease. |
| Keywords: | Dendritic Cell, Gene Transfer, Immunotherapy, Mucin (MUC1), Vaccine |
| Source: | Cancer Immunology Immunotherapy |
| ISSN: | 0340-7004 |
| Publisher: | Springer |
| Volume: | 51 |
| Number: | 11-12 |
| Page Range: | 669-673 |
| Date: | December 2002 |
| Official Publication: | https://doi.org/10.1007/s00262-002-0317-z |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
